TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT …

New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection at 1/6 of Oral Tacrolimus Dose and with 2/3 of Oral Tacrolimus Systemic Trough Exposures 4 out of 4…#tacrolimusdose #havechosen #remain #tac #safetyextensionphase #tffpharmaceuticals #tffp #thinfilmfreezingtff #phase2 #tacrolimusinhalation
Source: Reuters: Health - Category: Consumer Health News Source Type: news